WST (West Pharmaceutical Services) LT-Debt-to-Total-Asset : 0.08 (As of Sep. 2024)

View and export this data going back to 1980. Start your Free Trial

What is West Pharmaceutical Services LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. West Pharmaceutical Services's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.08.

West Pharmaceutical Services's long-term debt to total assets ratio increased from Sep. 2023 (0.06) to Sep. 2024 (0.08). It may suggest that West Pharmaceutical Services is progressively becoming more dependent on debt to grow their business.

West Pharmaceutical Services LT-Debt-to-Total-Asset Historical Data

The historical data trend for West Pharmaceutical Services's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

West Pharmaceutical Services LT-Debt-to-Total-Asset Chart

West Pharmaceutical Services Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.14

0.11

0.08

0.04

West Pharmaceutical Services Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.06	0.04	0.04	0.05	0.08

West Pharmaceutical Services LT-Debt-to-Total-Asset Calculation

West Pharmaceutical Services's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	157.3	/	3829.5
	=	0.04

West Pharmaceutical Services's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	284.9	/	3675.1
	=	0.08

West Pharmaceutical Services (NYSE:WST) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

West Pharmaceutical Services LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of West Pharmaceutical Services's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

West Pharmaceutical Services Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » West Pharmaceutical Services Inc (NYSE:WST) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

WST:Mexico WPS:Germany WPS:Germany W2ST34:Brazil

Address

530 Herman O. West Drive, Exton, PA, USA, 19341-1147

Website

https://www.westpharma.com

West Pharmaceutical Services is based in Pennsylvania, us, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

Executives

Charles Witherspoon	officer: VP & Treasurer	530 HERMAN O WEST DRIVE, EXTON PA 19341
Eric Mark Green	officer: Chief Executive Officer	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Silji Abraham	officer: Chief Digital & Trans Officer	5000 TOWN CENTER, U, SOUTHFIELD MI 48075
Thomas W Hofmann	director	FIVE RADNOR CORPORATE CENTER, SUITE 500, RADNOR PA 19087
Chad Winters	officer: VP, CAO & Controller	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Annette F Favorite	officer: Sr. VP Human Resources Officer	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Cindy Reiss-clark	officer: Senior Vice President	530 HERMAN O. WEST DRIVE, EXTON PA 19341-1147
Quintin J Lai	officer: VP Corp Development & Strategy	530 HERMAN 0. WEST DRIVE, EXTON PA 19341
Bernard Birkett	officer: Sr VP, CFO & Treasurer	1600 WEST MERIT PARKWAY, SOUTH JORDAN UT 84095
Stephen H Lockhart	director	C/O NATIONAL RESEARCH CORPORATION, 1245 Q STREET, LINCOLN NE 68508
Molly Joseph	director	9209 GRAND SUMMIT BLVD, DRIPPING SPRINGS TX 78620
Kimberly Banks Mackay	officer: SVP, GC & Corporate Secretary	530 HERMAN O. WEST DRIVE, EXTON PA 19341
George Lloyd Miller	officer: Sr. VP, GC & Corp. Sec.	530 HERMAN O. WEST DRIVE, EXTON PA 19341
David A Montecalvo	officer: SVP, Glob Ops and Supply Chain	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Robert F Friel	director	940 WINTER STREET, WALTHAM MA 02451